10 years of stem cell storage

November 18, 2010 Group News

Cryo-Save celebrates 10 years of stem cell storage with increasing usage of umbilical cord stem cells

Cryo-Save Group N.V. (“Cryo-Save”) is Europe’s leading stem cell bank, and today announces the 10 year anniversary of storing the first samples of stem cells taken from umbilical cord blood in its laboratories.

Since the first samples were stored, Cryo-Save has grown into one of the world leaders in private stem cell storage, with a record number of over 170,000 customers. The Group now operates in 40 countries on three continents, with five state-of-the-art laboratories processing and storing samples. No other stem cell bank matches Cryo-Save’s geographic spread.

Umbilical cord blood stem cells have been used for over 20 years and have proven their safety and efficacy in many treatments. Currently cord blood stem cells are more used for stem cell transplantations than bone marrow. Currently in the US, cord blood stem cells are the most frequently used source of stem cells for transplantation in the paediatric setting and adult transplantations using cord blood stem cells are on the rise. Furthermore, following years of preclinical research, clinical studies are now being conducted using cord blood stem cells for cellular therapy, for e.g. diabetes type 1, cerebral palsy and spinal cord injuries, with encouraging results.

Over the last decade, cord blood stem cell transplantations using samples released from Cryo-Save’s banks have saved the lives of children for treatments for diseases such as leukaemia and cerebral palsy, and have enabled families to carry out genetic testing.

In 2008, a study* reported comprehensive estimates of the odds of a person in the U.S. receiving a hematopoietic stem cell transplant, including cord blood stem cells, bone marrow stem cells and peripheral blood stem cells. The study estimated the odds of receiving one’s own cells for transplant at approximately 1 in 400.

*Nietfeld JJ. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol. Blood Marrow Transplant. 2008, 14:316-322

During the last ten years, Cryo-Save has worked relentlessly to increase the acceptance and awareness of the value of stem cell storage around the world. The Group continues its programme of educating and informing the public and healthcare professionals, to help ensure all expectant parents are aware of the options available to them and opportunity to store their child’s stem cells.

Cryo-Save continues to participate in adult stem cell research projects funded by the European Commission and is the only cord blood bank in Europe to take part in these advanced projects. The Group is also active in clinical studies for stem cell therapies and is pleased to be able to contribute to the medical community, working to improve quality of life.


Arnoud van Tulder, Chief Executive officer, commented:

Since our start in 2000, quality, reliability and service to our clients have been important pillars on which we have and continue to build our company. As leading stem cell bank in Europe we have extended our services and can offer today the storage of stem cells from umbilical cord and adult fat tissue in addition to stem cells from umbilical cord blood.


The significance of stem cell storage continues to grow as medical advances widen the potential for its use. Cryo-Save considers therefore supporting the R&D in this area as another important corporate activity. We will continue collaborating with centers of excellence that contribute to saving the lives of children and adults alike by developing additional stem cell treatments.


PDF Downloads

Press Release


Cryo-Save Group
+ 31 (0)575 548998
Arnoud van Tulder, Chief Executive Officer

SPJ Financiële Communicatie Amstelveen (NL)
+ 31 (0)20 647 8181
Kees Jongsma/Léon Melens

Daniel Stewart & Company plc
+ 44 (0) 20 7776 6550
Chris Theis

College Hill (UK)
+ 44 (0) 20 7457 2020
Adrian Duffield/Rozi Morris

Free footage is available on www.videobankonline.com.

Related Articles